# A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

> **NCT00001026** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 56 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** gp160 Vaccine (Immuno-AG)
- **BIOLOGICAL:** rgp120/HIV-1IIIB
- **BIOLOGICAL:** rgp120/HIV-1MN
- **BIOLOGICAL:** rgp120/HIV-1 SF-2
- **BIOLOGICAL:** HIVAC-1e

## Key facts

- **NCT ID:** NCT00001026
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1994-12
- **Target enrollment:** 56 (—)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001026, "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*